AstraZeneca to boost revenue, release new medicines by 2030

AstraZeneca to boost revenue, release new medicines by 2030

The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have … Read more

Merck (MRK) Q4 earnings report 2023

Merck (MRK) Q4 earnings report 2023

The logo for Merck & Co. is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021.  Andrew Kelly | Reuters Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda … Read more

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium.  NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a … Read more

Renewed interest in ADCs will continue in 2024

Renewed interest in ADCs will continue in 2024

Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. … Read more